Reverse merger of two public companies?

I was reading a bit into Valeant Pharmaceuticals and their previous merger with Biovail. A lot of news are talking about a "reverse merger" in this case "because Biovail keeps 50.5% of the shares." Now, I don't get what this is supposed to mean. When I read about reverse mergers, it is basically a fast and cheap way to take a private company public. But both Valeant and Biovail were previously public, and I though the only reason why Biovail acquired Valeant and not vice versa was for the reason that they can get low Canadian tax?

Can someone help me understand this correctly? Maybe its just the term "reverse merger" thats confusing me.

4 Comments
 

Yes, the tax implications and part of the reason it is structured that way because the new company would ostensibly be domiciled in Canada and thus the lower tax rate. I believe the only reason this is really a 'reverse merger' is that Biovail takes on the name of the company they are taking over, even though their shareholders would have a majority in the new combined company. I believe that is what is going on, although I haven't read up much on reverse mergers.

 

I think you're thinking of a Inversion deal. An Inversion is a type of merger where a company either buys out or is bought by a foreign owned company in order to take advantage of the foreign tax rate. Bioavail was the acquiring company even though the company kept the Valeant name. Medtronic is another great example. Medtronic acquired Covidien, an Irish medical device company, and reincorporated under Irish Law as Medtronic PLC with a listing on the NYSE as MDT in order to pay a significantly reduced tax burden.

 

Confused by this too. Was thinking similar to Frieds and thought you might have confused it for n tax inversion trade/deal like Warner Chilcott/Actavis.

 

Est repellat ut dolor similique ad est itaque sequi. Nemo omnis non totam et est sed quo. Quaerat ducimus fugit delectus magni commodi autem omnis.

Earum dolore velit repudiandae quia nesciunt. Voluptates non culpa nulla repudiandae pariatur et. Et similique enim eveniet dolores. Vitae ut in voluptas rerum nisi.

Autem est assumenda ipsam perspiciatis dolorem eius debitis. Velit nam mollitia reprehenderit.

Amet reiciendis distinctio et dolor sed. Culpa odit provident amet. Rerum molestiae ipsa vero dolor molestiae repudiandae id.

Career Advancement Opportunities

October 2026 Investment Banking

  • Evercore 01 99.5%
  • Moelis & Company 01 99.0%
  • JPMorgan 01 98.4%
  • Guggenheim Partners 02 97.9%
  • Morgan Stanley 06 97.4%

Overall Employee Satisfaction

October 2026 Investment Banking

  • Moelis & Company No 99.5%
  • Morgan Stanley 02 99.0%
  • Evercore 01 98.4%
  • Banco Santander 02 97.9%
  • BMO Capital Markets 13 97.4%

Professional Growth Opportunities

October 2026 Investment Banking

  • Evercore 01 99.5%
  • Moelis & Company 01 99.0%
  • Morgan Stanley 05 98.4%
  • Goldman Sachs 01 97.9%
  • JPMorgan No 97.4%

Total Avg Compensation

October 2026 Investment Banking

  • Vice President (16) $429
  • Associates (57) $264
  • 3rd+ Year Analyst (8) $210
  • 2nd Year Analyst (28) $184
  • Intern/Summer Associate (16) $161
  • 1st Year Analyst (84) $151
  • Intern/Summer Analyst (76) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
kanon's picture
kanon
99.0
3
Secyh62's picture
Secyh62
99.0
4
BankonBanking's picture
BankonBanking
99.0
5
dosk17's picture
dosk17
98.9
6
GameTheory's picture
GameTheory
98.9
7
DrApeman's picture
DrApeman
98.9
8
Betsy Massar's picture
Betsy Massar
98.9
9
CompBanker's picture
CompBanker
98.9
10
numi's picture
numi
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”